INFARMATIK, INC. DESIGNED many targeted fragment which could be divided into two major fragment types
The primary goal is to commercialize this 1700 fragents set. However, InFarmatik, Inc. is ready to participate on drug dicovery project, on risk sharing basis. There is no particular project preference to fragment type vs program, but so far majority of the coordinative fragments went to GPCR research (GPR84) and Covalent Fragments have been used in Oncology Programs (INHIBILLION).
Please write an email, if you would like to participate in programs or would like to suggest another risk-sharing program.
For structures please contact EvoBlocks sales